TARSUS PHARMACEUTICALS, INC. Accumulated Amortization, Debt Issuance Costs
TARSUS PHARMACEUTICALS, INC. (TARS) had Accumulated Amortization, Debt Issuance Costs of $1.28 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Debt
us-gaap:AccumulatedAmortizationDeferredFinanceCosts · last filed 2026-08-06
- 2026-06-30: Accumulated Amortization, Debt Issuance Costs $1.28M.
- 2026-03-31: Accumulated Amortization, Debt Issuance Costs $1.12M.
- 2025-12-31: Accumulated Amortization, Debt Issuance Costs $961.00K.
- 2025-09-30: Accumulated Amortization, Debt Issuance Costs $804.00K.
| Period end | Accumulated Amortization, Debt Issuance Costs |
|---|---|
| 2026-06-30 | $1.28M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.12M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $961.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $804.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | $652.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $507.00K 10-Q · filed 2025-05-01 |
| 2024-12-31 | $368.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | $231.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $101.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $291.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $256.00K 10-K · filed 2025-02-25 |
| 2023-09-30 | $225.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $193.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $164.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $135.00K 10-K · filed 2024-02-27 |
| 2022-09-30 | $104.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $58.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $23.00K 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |